Management of Coronary Artery Calcification
For adults with coronary artery calcification detected on imaging, management should be guided by the CAC score to determine statin therapy intensity, with CAC ≥100 warranting high-intensity statin therapy and aspirin 81 mg daily, while CAC = 0 allows deferral of statin therapy in appropriate candidates. 1
Risk Stratification Framework
The CAC score serves as the single best predictor of 5- to 10-year atherosclerotic cardiovascular disease (ASCVD) event risk 1. Management decisions should follow this algorithmic approach:
For Borderline to Intermediate-Risk Adults (Ages 40-75)
- Definition: LDL-C 70-189 mg/dL with 10-year ASCVD risk 5-19.9%
- Action: Use CAC scoring to determine need for and intensity of preventive therapies 1
For Low-Risk Adults (Age ≥40)
- Definition: LDL-C 70-189 mg/dL with 10-year ASCVD risk <5%
- Action: CAC scoring reasonable for selective patients with strong family history of premature ASCVD 1
Specific Treatment Thresholds
CAC Score = 0
- Defer statin initiation in adults 40-75 years without diabetes, active smoking, or family history of premature ASCVD 1
- For ages 76-80 where statin therapy is uncertain, CAC = 0 favors avoidance of therapy 1
- Repeat CAC scanning in 3-7 years 1
- This identifies a low-risk subgroup even among guideline-eligible patients, with CVD event rate of only 1.6% 2
CAC Score ≥100
- Initiate high-intensity statin therapy 1
- Add aspirin 81 mg daily 1
- Number needed to treat ranges from 11-26 to prevent one ASCVD event over 10 years 3
CAC Score ≥300
- Strongly recommend high-intensity statin therapy 1
- Consider more aggressive risk factor modification
- Do NOT routinely perform stress testing or invasive coronary angiography if asymptomatic, even with predominant left main coronary calcification or multivessel involvement 1
International Guideline Variations
Different regions apply CAC scoring with slight variations:
- United States/Canada: CAC as arbitrator of statin use in intermediate risk 1
- Europe: CAC for risk reclassification in diabetes patients (type 1 DM <35 years, type 2 DM <50 years with duration <10 years and no other risk factors) 1
- United Kingdom: CAC for adjudicating statin allocation, including asymptomatic patients with ECG changes suggesting ischemia 1
- China: CAC as arbitrator for aspirin allocation 1
- Australia: CAC indicated in low-risk patients with strong family history or concerning features, and high-risk patients reluctant to accept treatment 1
The ESC/EAS guidelines identify substantially more CAC-eligible individuals (46.6% of men, 44.9% of women) compared to ACC/AHA guidelines using PREVENT equations (13.4% of men, 3.4% of women) 3, though both approaches improve risk stratification at acceptable treatment thresholds.
Incidental CAC Findings on Non-Cardiac CT
When CAC is detected incidentally on non-gated chest CT performed for other indications:
- Report CAC presence and severity using simple grading (none, mild, moderate, severe) 4
- This finding has prognostic implications across all age groups 5
- The "number needed to report" is only 2 to potentially impact management 5
- Recommend assessment of modifiable cardiovascular risk factors 4
- If patient has chest pain, assess per standard guidelines 4
- Severe calcification independently predicts all-cause mortality (HR 1.8) 5
Critical Pitfalls to Avoid
- Do not order stress testing or invasive angiography based solely on high CAC scores in asymptomatic patients 1
- Do not ignore CAC = 0 in patients otherwise considered for statin therapy—this finding allows safe deferral 1, 2
- Do not fail to report incidental CAC on non-cardiac CT scans—this represents actionable information with clear treatment implications 4, 5
- Do not apply CAC scoring to patients with established clinical ASCVD—they already warrant maximal medical therapy 1
Baseline Statin Therapy
Regardless of CAC score, all patients with established chronic coronary syndrome require high-intensity statin therapy up to the highest tolerated dose to reach LDL-C goals 6. The CAC score primarily guides primary prevention decisions, not secondary prevention where statins are already indicated.